Speciality Medicines profit jumps 81% in first year post-listing
The Ahmedabad-based firm reported annual revenue of ₹75.29 crore, while confirming the initial deployment of its ₹29.14 crore IPO proceeds.
What's new
- Annual revenue rose 29% to ₹75.29 crore for the fiscal year ended March 31, 2026.
- Net profit reached ₹13.03 crore, an 81% increase over the prior year.
- The company deployed ₹5.09 crore of its ₹29.14 crore IPO funds into R&D and product registrations.
Why this matters
For a company with a market capitalization of ₹192 crore, an 81% profit expansion is a sharp opening performance. The clean report on IPO fund usage provides early comfort to investors regarding capital allocation.
What we're watching
- Whether the R&D center in Gujarat translates into new product launches in FY27.
- The pace of international product registrations.
- Sustainability of the 17% net margin in the coming quarters.
The full read
Speciality Medicines posted a strong debut year following its March 2026 SME listing. The Ahmedabad-based firm grew annual revenue by 29% to ₹75.29 crore, while net profit surged 81% to ₹13.03 crore.
Profitability is soaring.
For a company with a market capitalization of ₹192 crore, this level of expansion is a clear indicator of operational scale, especially as the company simultaneously provided a clean update on its ₹29.14 crore IPO, confirming that ₹5.09 crore has already been deployed into R&D facilities and international product registrations without any reported deviations in fund utilization. The company has cleared its first post-listing hurdle. The next test is whether it can maintain this growth trajectory as it scales its R&D capabilities.
Questions answered
- How much profit did Speciality Medicines generate in FY26?
- The company reported a net profit of ₹13.03 crore for the fiscal year ended March 31, 2026, representing an 81% increase.
- What is the status of the company's IPO proceeds?
- Speciality Medicines raised ₹29.14 crore in its IPO and has deployed ₹5.09 crore toward an R&D center in Gujarat and international product registrations. The company reported no deviations in the use of these funds.
- What was the revenue growth for the year?
- Annual revenue grew 29% to ₹75.29 crore for the fiscal year ended March 31, 2026.
- What is the current market scale of the company?
- Speciality Medicines is a nano-cap entity with a market capitalization of ₹192 crore.